Primary Health Properties PLC
Director's & PDMR dealings
On 21 February 2023, the remuneration committee of Primary Health Properties PLC (the "Company" or "PHP") made the following awards of nil-cost options under the Company's 2021 Long-term Incentive Plan ("LTIP") to a Director and Persons Discharging Managerial Responsibilities ("PDMR's").
| Director | Number of shares under option |
| Richard Howell | 414,874 |
| PDMR | |
| David Bateman | 267,363 |
The number of nil-cost options were calculated by reference to a price of £1.08, being the average of the closing middle market quotations for the Company's ordinary shares on 22 February 2023, 23 February 2023 and 24 February 2023.
The nil-cost options will normally vest on the third anniversary of grant, subject to the attainment of performance conditions. The remuneration committee has the discretion to adjust the awards downwards at vesting for malus reasons. Details of the operation of the LTIP are set out in the Company's 2021 Report and Accounts.
Details of the transactions referenced above are included below in accordance with the under Article 19 of the retained EU law version of the Market Abuse Regulation (Regulation 596/2014).
| 1 | Details of Person Discharging Managerial Responsibility/person closely associated with them ("PCA") | ||
| (a) | Name | Richard Howell
| |
| 2 | Reason for the notification | ||
| (a) | Position/status | Chief Financial Officer | |
| (b) | Initial notification/ amendment | Initial notification
| |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||
| (a) | Name of Entity
| Primary Health Properties PLC | |
| (b) | Legal Entity Identifier | 213800Y5CJHXOATK7X11
| |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date: and (iv) each place where transactions have been conducted | ||
| (a) | Description of the financial instrument | Ordinary shares of 12.5p ISIN: GB00BYRJ5J14 | |
| (b) | Nature of the transaction | Award of nil-cost options over the Company's ordinary shares
| |
| (c) | Aggregated information Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil cost | 414,874
| ||
| (d) | Aggregated volume price | Single transaction: N/A
| |
| (e) | Date of transaction | 27 February 2023
| |
| (f) | Place of transaction | n/a
| |
| 1 | Details of Person Discharging Managerial Responsibility/person closely associated with them ("PCA") | ||
| (a) | Name | David Bateman
| |
| 2 | Reason for the notification | ||
| (a) | Position/status | PDMR | |
| (b) | Initial notification/ amendment | Initial notification
| |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||
| (a) | Name of Entity
| Primary Health Properties PLC | |
| (b) | Legal Entity Identifier | 213800Y5CJHXOATK7X11
| |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date: and (iv) each place where transactions have been conducted | ||
| (a) | Description of the financial instrument | Ordinary shares of 12.5p ISIN: GB00BYRJ5J14 | |
| (b) | Nature of the transaction | Award of nil-cost options over the Company's ordinary shares
| |
| (c) | Aggregated information Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil cost | 267,363
| ||
| (d) | Aggregated volume price | Single transaction: N/A
| |
| (e) | Date of transaction | 27 February 2023
| |
| (f) | Place of transaction | n/a
| |
More information on Primary Health Properties PLC can be found on www.phpgroup.co.uk
Further details:
| Harry Hyman Chief Executive Officer Tel: +44 (0) 20 7451 7050 | Steven Owen Chairman Tel: +44 (0) 20 7451 7050 |
| Richard Howell Chief Financial Officer Tel: +44 (0) 203 8333 342 | |
| David Rydell / Steph Watson (Buchanan Communications) Tel: +44 (0) 20 7466 5066 | |
Legal Entity Identifier: 213800Y5CJHXOATK7X11
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
